Conferences

Press

Fabric Genomics, a global computational genomics company, and Veritas Genetics, the global leader in genetic sequencing and interpretation, announced today at the ACMG Annual Clinical Genetics Meeting that they have entered into a technology partnership. The goal of the collaboration is to accelerate Veritas’ myGenome product for personal whole genome sequencing using Fabric Genomics’ new …

Read More

Fabric Genomics, a global computational genomics company, and Sentieon, which develops highly optimized algorithms for bioinformatics applications, today announced a technology partnership that will enhance Fabric Genomics’ secondary analysis capabilities within Fabric Enterprise™, the company’s new end-to-end precision medicine platform. Fabric Genomics’ new secondary analysis offering, Fabric Standard™, is 10 times faster than commonly adopted …

Read More

Omicia today announced that it has rebranded and renamed the organization to better reflect the company’s ability to uniquely deliver clinical quality genomic data insights. Now known as Fabric Genomics TM, the company revealed its new name, logo and brand identity at this week’s ACMG Annual Clinical Genetics Meeting. The company also launched Fabric EnterpriseTM, …

Read More

With Acquisition, Omicia Adds Secondary NGS Analysis and Structural Variant Capabilities Omicia, Inc., a leading provider of clinical genomic data analysis and reporting software, announced today that it has acquired Seattle-based Spiral Genetics. Spiral’s advanced tools add multiple variant detection capabilities for next generation sequencing (NGS) to Omicia’s industry-leading software platform. Omicia now offers a …

Read More

Omicia, Inc., a leading provider of clinical genomic data analysis and reporting tools, was selected to join the Cancer Moonshot’s Blood Profiling Atlas in Cancer (Blood PAC) consortium. In joining Blood PAC, Omicia is demonstrating its commitment to advancing cancer genetics research and extending patients’ lives. The Blood PAC was formed in October 2016 in …

Read More

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, announced today that San Diego-based Rady Children’s Institute for Genomic Medicine has chosen the company as their first line genome interpretation partner for the implementation of Rady Children’s rapid genome testing in their neonatal and pediatric intensive care units (NICU/ PICU). Stephen Kingsmore, …

Read More

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, announced today that it has delivered more than 500 clinical reports for the 100,000 Genomes Project, and has begun to return clinical reports for the project’s main program. These clinical reports are being delivered to Genomics England, leader of the 100,000 Genomes Project, and …

Read More

In the recent article “The DNA of a Nation,” Nature magazine highlights the highly-specialized and dedicated clinical interpretation services that Genomics England requires for their 100,000 Genomes Project, which is the first step in bringing genomics to the UK healthcare system. Omicia, the worldwide leader in genome informatics and clinical interpretation, was selected from 28 …

Read More

Omicia, Inc., a leading provider of clinical genome interpretation and reporting software, today announced the completion of a $23 million Series B financing round. Several new investors participated in the round, including UPMC Enterprises, Roche Venture Fund, LDV Partners, Ping An Ventures, and a large genomics investor, as well as existing investors ARTIS Ventures, Acadia …

Read More